EAY191 (ComboMATCH) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to identify patients who have gene changes or mutations in their tumor(s) and might be eligible for treatment using a combination of targeted therapy options. This study is called ComboMATCH (Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice).
Cancers that do not respond to standard treatment options
Who Can Participate in the Study?
Adults ages 18+ who:
- Have measurable disease
- Are deemed potentially eligible for a ComboMATCH Treatment Trial as assessed by the enrolling provider
- Have progressed after one course of standard therapy or are not able to be treated with standard therapy
For more information about this study, please contact the study team at nick.jeffries@duke.edu.
What is Involved?
This study is a registration study to see who might be eligible for upcoming ComboMATCH drug trials.
If you choose to join, you will have a sample of your tumor tested by a ComboMATCH-designated laboratory. If the tests show that you may be able to participate in the ComboMATCH program, the results and some of your health information will be sent by your doctor or the ComboMATCH-designated laboratory to Precision Medicine Analysis Coordination Center (PMACC) to be used to determine if you are eligible for a ComboMATCH treatment trial.
You can read more about ComboMATCH on the National Cancer Institute website: https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/combomatch
Study Details
